TrialESMO open2022

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

L Paz-Ares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.